The inaugural ARDS Drug Development Summit will bring 60+ biopharma leaders together to discover how the rise of SARS-CoV-2 ARDS, emergence of novel targets, and the past 12 months of unprecedented global focus on ARDS research has transformed this graveyard of drug development failures into a starting point for the next generation of therapeutics addressing not just ARDS, but broader, systemic inflammation.

Virtually uniting dedicated and experienced industry experts from Aqualung, Bone Therapeutics, Boehringer Ingelheim, Athersys and more, this trailblazing new meeting will help you overcome your most urgent drug development challenges.